Uma abordagem filosófica e histórica da arte cognitiva e informacional

Neste estudo, Uma abordagem filosófica e histórica da arte cognitiva e informacional, abordase a arte feita na intersecção entre a ciência e a tecnologia, habitualmente designada new media art (arte dos novos meios técnicos), e propõe-se a designação de arte cognitiva e informacional. Esta proposta é feita concomitantemente com a análise do projecto definicional para a arte computacional e para a arte digital de Dominic McIver Lopes, presente em A Philosophy of Computer Art, e recorre também a conceitos presentes na teoria ontológica da arte de David Davies, Art as Performance, e no ensaio de Sherri Irvin, The Artist's Sanction in Contemporary Art. Constrói-se de seguida uma narrativa histórica para a arte biológica, com base numa proposta filosófica de Noël Carroll, esperando contribuir-se, através deste sub-género, para que o grande género da arte cognitiva e informacional seja plenamente integrado nas histórias canónicas das artes visuais dos séculos XX e XXI.Abstract: A philosophical and historical approach to cognitive and informational art is a study about the art made in the intersection between science and technology, usually designated new media art. We propose a new designation, cognitive and informational art, during the discussion of the definitions of computer art and digital art, present in Dominic McIver Lopes' A Philosophy of Computer Art; and also by using concepts developed by David Davies in Art as Performance, and in Sherri Irvin's essay The Artist's Sanction in Contemporary Art. We proceed by developing a historical narrative specifically to bioart, hoping that, through this sub-genre, the main genre (cognitive and informational art) can become a part of the canonical historiography on the visual arts of the 20th and 21th centuries

SARS-CoV-2 introductions and early dynamics of the epidemic in Portugal

Genomic surveillance of SARS-CoV-2 in Portugal was rapidly implemented by the National Institute of Health in the early stages of the COVID-19 epidemic, in collaboration with more than 50 laboratories distributed nationwide. Methods By applying recent phylodynamic models that allow integration of individual-based travel history, we reconstructed and characterized the spatio-temporal dynamics of SARSCoV-2 introductions and early dissemination in Portugal. Results We detected at least 277 independent SARS-CoV-2 introductions, mostly from European countries (namely the United Kingdom, Spain, France, Italy, and Switzerland), which were consistent with the countries with the highest connectivity with Portugal. Although most introductions were estimated to have occurred during early March 2020, it is likely that SARS-CoV-2 was silently circulating in Portugal throughout February, before the first cases were confirmed. Conclusions Here we conclude that the earlier implementation of measures could have minimized the number of introductions and subsequent virus expansion in Portugal. This study lays the foundation for genomic epidemiology of SARS-CoV-2 in Portugal, and highlights the need for systematic and geographically-representative genomic surveillance.We gratefully acknowledge to Sara Hill and Nuno Faria (University of Oxford) and Joshua Quick and Nick Loman (University of Birmingham) for kindly providing us with the initial sets of Artic Network primers for NGS; Rafael Mamede (MRamirez team, IMM, Lisbon) for developing and sharing a bioinformatics script for sequence curation (https://github.com/rfm-targa/BioinfUtils); Philippe Lemey (KU Leuven) for providing guidance on the implementation of the phylodynamic models; Joshua L. Cherry (National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health) for providing guidance with the subsampling strategies; and all authors, originating and submitting laboratories who have contributed genome data on GISAID (https://www.gisaid.org/) on which part of this research is based. The opinions expressed in this article are those of the authors and do not reflect the view of the National Institutes of Health, the Department of Health and Human Services, or the United States government. This study is co-funded by Fundação para a Ciência e Tecnologia and Agência de Investigação Clínica e Inovação Biomédica (234_596874175) on behalf of the Research 4 COVID-19 call. Some infrastructural resources used in this study come from the GenomePT project (POCI-01-0145-FEDER-022184), supported by COMPETE 2020 - Operational Programme for Competitiveness and Internationalisation (POCI), Lisboa Portugal Regional Operational Programme (Lisboa2020), Algarve Portugal Regional Operational Programme (CRESC Algarve2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF), and by Fundação para a Ciência e a Tecnologia (FCT).info:eu-repo/semantics/publishedVersio

O31 Integrative analysis reveals a molecular stratification of systemic autoimmune diseases

n/

Ranibizumab for the treatment of diabetic macular oedema in the real-world clinical setting in Portugal : a multicentre study

© 2018 S. Karger AG, BaselPurpose: The purpose of this study was to evaluate the 2-year outcome of ranibizumab for diabetic macular oedema (DME) in the real-life clinical practice of five ophthalmology departments of the National Health Service (NHS) in Portugal. Methods: This is a retrospective multicentre study. The clinical records on consecutive patients with DME from clinical practice treated with 0.5 mg intravitreal ranibizumab and followed up for 24 months were reviewed. Efficacy outcomes comprised the change in best corrected visual acuity (BCVA) and central macular thickness (CMT) evaluated by SD-OCT. Multivariate regression analysis was performed to explore predictors of BCVA. Results: A total of 122 eyes of 93 patients were included. The median BCVA change by 24 months was +5.0 letters (IQR 12.0) (p < 0.001) and the CMT change was –89.0 µm (IQR 165.0) (p < 0.001). By 24 months, 21.4% of the eyes had gained ≥15 letters and 8.6% had lost ≥15 letters. The median number of injections given during follow-up was 5.0 (IQR 4.0). A greater baseline CMT and a more disrupted status of the external limiting membrane were predictive of worse BCVA at 24 months (p ≤ 0.015). Conclusion: DME treatment with ranibizumab in the Portuguese NHS is associated with anatomic and functional improvement by 2 years; however, our results are below those reported in major clinical trials, and undertreatment is probably the cause.info:eu-repo/semantics/publishedVersio